CD19 CAR T-Cell Therapy | Revolutionizing Cancer Treatment | Michel Sadelain’s 'Living Drugs'

preview_player
Показать описание

  1. Nerd Nucleus
Рекомендации по теме
CD19- and CD22-Directed 0:02:36

CD19- and CD22-Directed Chimeric Antigen Receptor T-Cell Therapy in Childhood B-Cell ALL

CD19 CAR T-cell 0:02:55

CD19 CAR T-cell therapy for lymphoma

Dr. Shah on 0:01:29

Dr. Shah on Differences Between Anti–CD19 CAR T-Cell Therapies

Bispecific CAR T-cell 0:00:45

Bispecific CAR T-cell therapy: combining anti-CD19 and CD22 CAR T-cells

CD19 CAR T 0:57:03

CD19 CAR T Cell Therapy for Pediatric ALL: The Seattle Children’s Experience

CD19 Targeted CAR 0:45:46

CD19 Targeted CAR T-cell Therapy in LBCL

Dr. Smith Discusses 0:00:56

Dr. Smith Discusses CD19 CAR T-Cell Therapy in B-ALL

Safety profile of 0:01:11

Safety profile of anti-CD19 CAR T-cell therapy axicabtagene ciloleucel

51 Inmunoterapia CAR 1:01:47

51 Inmunoterapia CAR T la nueva era en el abordaje del cáncer hematológico

Advancements and challenges 0:02:53

Advancements and challenges in CAR-T cell therapy

Lymphoma: Overview of 0:06:13

Lymphoma: Overview of Chimeric Antigen Receptor (CAR) T cells

Key questions in 0:04:24

Key questions in the field of CD19 CAR T-cell therapy

CAR T-Cell Therapy: 0:02:21

CAR T-Cell Therapy: How Does It Work?

Anti-CD22 CAR T-cell 0:01:21

Anti-CD22 CAR T-cell therapy for ALL: trial update, utility for salvage and CD19 status

CD19 CAR T-cells 0:04:47

CD19 CAR T-cells for adults

CD19 CAR T 0:18:59

CD19 CAR T Cell Therapy in SLE (9.16.2022)

Risk factors to 0:04:05

Risk factors to predict post-CD19 CAR-T cell therapy outcomes in patients with LBCL

CD19 CAR-T for 0:01:39

CD19 CAR-T for CNS lymphoma

Diminished chronic GvHD 0:01:57

Diminished chronic GvHD symptoms following anti-CD19 CAR T-cell therapy: a case study

Humanized versus murinized 0:03:34

Humanized versus murinized CD19/CD22 CAR-T cell therapy for R/R B-cell lymphoma

Side effects of 0:01:11

Side effects of CAR T-cell therapy

CD19-Targeted CAR T-Cell 0:08:33

CD19-Targeted CAR T-Cell Therapy in Managing DLBCL

Evaluating post-infusion CAR-Treg 0:01:29

Evaluating post-infusion CAR-Treg cells to identify patients resistant to CD19 CAR-T therapy

Checkpoint inhibitors augument 0:07:19

Checkpoint inhibitors augument CD19 CAR T-cell therapy in relapsed B-ALL